Pac-Link
VC Fund
Taipei, Taiwan
Pac-Link is a venture capital firm.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 24%
Last updated:
For AI agents: llms.txt
Industries Pac-Link invests in
BiotechnologyHealth CareMedicalTherapeuticsWireless
Stages Pac-Link invests in
Series BFunding RoundSeries CSeries DSeries F
Countries Pac-Link invests in
United StatesCanadaChinaTaiwan
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Chin-Ming Wang
|
|||
Chris Zing
|
|||
|
Jessica Huang
|
|||
|
Neil Wu
|
|||
|
Richard Chong
|
Investment Focus
Industry
- Biotechnology 7 (41%)
- Health Care 5 (29%)
- Medical 4 (24%)
- Therapeutics 4 (24%)
- Wireless 3 (18%)
Stage
- Series B 6 (35%)
- Funding Round 4 (24%)
- Series C 2 (12%)
- Series D 2 (12%)
- Series F 1 (6%)
Country
- United States 10 (59%)
- Canada 2 (12%)
- China 1 (6%)
- Taiwan 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Chin-Ming Wang
VP, Partner
|
VP, Partner | Total investments: 0 | Find email | |
|
Chris Zing
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Jessica Huang
VP, Partner
|
VP, Partner | Total investments: 0 | Find email | |
|
Neil Wu
VP, Partner
|
VP, Partner | Total investments: 0 | Find email | |
|
Richard Chong
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Revance Therapeutics
|
Revance Therapeutics is a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as EssentiaBiosystems. | $45M / Series D / Jun 10, 2011 | |
Synerchip
|
Synerchip is a semiconductor company who develops high-speed digital interface technology for consumer electronics networks to send and receive video, audio and data simultaneously to maximize the home entertainment experience. Synerchip develops Digital Interactive Interface for Video & Audio (DiiVA). DiiVA connects home electronics devicesthrough a network carrying video, audio, USB, and Ethernet. | $10.5M / Series C / Apr 20, 2010 | |
|
Revance Therapeutics
|
Revance Therapeutics is a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as EssentiaBiosystems. | $25.6M / Series D / Dec 28, 2009 | |
Broncus Technologies
|
Broncus Technologies is a medical technology company focused on developing minimally-invasive medical devices for emphysema and other lung diseases. Broncus is investigating the Exhale emphysema product line to perform our patented treatment method called Airway Bypass. Airway Bypass could be the first minimally-invasive procedure for the treatmentof homogeneous, or diffuse, emphysema, which constitutes the majority of the emphysema patient population.Broncus is currently enrolling patients worldwide in our pivotal EASE Trial investigating a treatment of severe homogeneous emphysema.Broncus is located in Mountain View, CA (San Francisco Bay area).Broncus International is located in Nyon, Switzerland. | $38M / Series G / Dec 05, 2008 | |
UltiZen
|
Ultizen Games Ltd. operates as a game development and offshore game outsourcing company in China. It involves in game design, level design, programming, art design, modeling, animation production, and testing services. The company offers online casual game PC, Xbox360 live arcade game, and U-PAL online casual game platform. Ultizen Games'outsourcing services include art design, 2D art production, 3D modeling, and animation production on various platforms; porting and networking; testing and localization; game development; and IPTV game development. The company serves North American, European, and Japanese companies. Ultizen Games Ltd. was founded in 2005 and is based in Shanghai, China. | $6M / Series B / Aug 05, 2008 | |
Portola Pharmaceuticals
|
Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedicsurgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California. | $60.1M / Series C / Jul 09, 2008 | |
Destinator Technologies
|
Destinator Technologies, Inc. provides navigation software for personal navigation devices and smart phones. It also offers software development kits for developing individual and company specific navigation solutions. The company serves consumer brands and mobile device manufacturers. The company was founded as Homeland Security TechnologyCorporation in 2003 and changed its name to Destinator Technologies, Inc. in 2005. The company is headquartered in Richmond Hill, Canada with additional offices in the United States, Canada, Germany, Israel, Taiwan, and China. As of July 9, 2008, Destinator Technologies Inc. operates as a subsidiary of Intrinsyc Software International Inc. | $7.5M / Sep 05, 2007 | |
Serenex
|
Serenex is a medical drug discovery and development company that focuses on oncology. The company develops Hsp90 product platform that provides a collection of small molecule Hsp90 inhibitors for cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases, such as Alzheimer's. It also developsSNX-1012, a product for oral mucositis in solid tumor patients.Serenex is a U.S.-based company that was founded in 2000 and it was acquired in 2008 by Pfizer. | $26M / Series D / Jun 28, 2007 | |
DiObex
|
DiObex, Inc. operates as a biotechnology company in the United States. The company develops novel products for the treatment of metabolic disorders, including type-one and type-two diabetes, dyslipidemia, obesity, and diabetic nephropathy. Its products include DIO-901, a very low dose glucagon product that is developed for the reduction ofnocturnal hypoglycemia in patients with type-one diabetes; and DIO-902, a cortisol synthesis inhibitor that is developed as a therapy for glucose and cholesterol control in patients with type-two diabetes. DiObex, Inc. was founded in 2003 and is based in San Francisco, California. | $24M / Series B / Apr 16, 2007 | |
Trellis Bioscience
|
Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact ofpotential therapeutic interventions. The company is based in San Francisco, California. | $10M / Series B / Feb 14, 2007 | |
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Health Care Investors
43,014 investors
Hardware Investors
40,144 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
SaaS VC Funds
61,208 investors
Health Care VC Funds
32,370 investors
Hardware VC Funds
30,945 investors
FAQ
What does Pac-Link invest in?
Pac-Link invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Funding Round stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Pac-Link?
Public channels for Pac-Link include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pac-Link?
The team at Pac-Link includes Chin-Ming Wang (VP, Partner), Chris Zing (Managing Director) and Jessica Huang (VP, Partner), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
